Opportunities and challenges following approval of resmetirom for MASH liver disease (original) (raw)

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

References

  1. Rinella, M. E. et al. Ann. Hepatol. 29, 101133 (2023).
    Article PubMed Google Scholar
  2. Younossi, Z. M. et al. Hepatology 77, 1335 (2023).
    Article PubMed Google Scholar
  3. Elizabeth, L. Y. & Schwimmer, J. B. Clin. Liver Dis. 17, 196 (2021).
    Article Google Scholar
  4. Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M. & Alkhouri, N. Nat. Med. 29, 562–573 (2023).
    Article CAS PubMed Google Scholar
  5. US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (2024).
  6. Harrison, S. A. et al. Nat. Med. 29, 2919–2928 (2023).
    Article CAS PubMed PubMed Central Google Scholar
  7. Cusi, K. Endocr. Pract. 28, 528–562 (2022).
    Article PubMed Google Scholar
  8. Gilmore, A. B. et al. Lancet 401, 1194–1213 (2023).
    Article PubMed Google Scholar
  9. Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Nat. Rev. Gastroenterol. Hepatol. 20, 708–722 (2023).
    Article CAS PubMed Google Scholar
  10. Asquith, E., Bould, K., Catling, J., Day, E. & Holt, A. BMC Gastroenterol. 23, 306 (2023).
    Article CAS PubMed PubMed Central Google Scholar
  11. Cannon, C. E. Int. J. Environ. Res. Public Health 17, 2303 (2020).
    Article PubMed PubMed Central Google Scholar
  12. Lazarus, J. V. et al. Hepatology 79, 502–523 (2024).
  13. Lazarus, J. V. et al. J. Hepatol. 79, 618–634 (2023).
    Article PubMed Google Scholar
  14. Ratziu, V. & Charlton, M. J. Hepatol. 78, 1073–1079 (2023).
  15. Lewis, K. H., Moore, J. B. & Ard, J. D. Obesity 32, 237–239 (2023).

Download references

Acknowledgements

J.V.L., D.I.W., H.E.M. and C.J.K. acknowledge support to ISGlobal from grant CEX2018-000806-S, funded by MCIN/AEI/10.13039/501100011033, and the ‘Generalitat de Catalunya,’ through the CERCA program, outside of the submitted work.

Author information

Authors and Affiliations

  1. City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA
    Jeffrey V. Lazarus & Nevin Cohen
  2. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
    Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Henry E. Mark & Christopher J. Kopka
  3. Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
    Jeffrey V. Lazarus
  4. Global NASH Council, Washington, DC, USA
    Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Henry E. Mark, Zobair M. Younossi & Paul N. Brennan
  5. Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, VA, USA
    Zobair M. Younossi
  6. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Meena B. Bansal
  7. Fatty Liver Alliance, Toronto, Ontario, Canada
    Michael Betel
  8. Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
    Paul N. Brennan

Authors

  1. Jeffrey V. Lazarus
  2. Dana Ivancovsky Wajcman
  3. Henry E. Mark
  4. Zobair M. Younossi
  5. Christopher J. Kopka
  6. Nevin Cohen
  7. Meena B. Bansal
  8. Michael Betel
  9. Paul N. Brennan

Corresponding author

Correspondence toJeffrey V. Lazarus.

Ethics declarations

Competing interests

J.V.L. acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer and Roche Diagnostics; consulting fees from Echosens, NovoVax, GSK, Novo Nordisk and Pfizer; and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk and Pfizer, outside of the submitted work. Z.M.Y. acknowledges consulting fees from Intercept, Cymabay, Boehringer Ingelheim, Bristol Myers Squibb, GSK, NovoNordisk, AstraZeneca, Siemens, Madridgal, Merck, Ipsen and Abbott, outside of the submitted work. M.B.B. acknowledges grants or contracts to her institution from the NIH, the CDC/NIOSH, Pfizer, the Kinetix Group and Histoindex; consulting fees from Kinetix, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK and Merck; and payment or honoraria from Madrigal, NOVO Nordisk and GSK, outside of the submitted work. M.B. acknowledges grants to the Fatty Liver Alliance from Madrigal Pharmaceuticals, Inventiva, Regeneron, Hoffmann-La Roche, the Global Liver Institute, Siemens Healthineers, Aegle Medical, Pfizer, the Canadian Liver Foundation, Altimmune, KNS Canada, Sentrex Health Solutions, Novo Nordisk, Intercept Pharmaceuticals and the Canadian Institute of Health Research; consulting fees from Hoffmann-La Roche, Madrigal Pharmaceuticals and the Global Liver Institute; payment or honoraria from Inventiva and MCI (grant to the Fatty Liver Alliance); and support for attending meetings and/or travel from Regeneron, Arizona Liver Health and the Liver Forum, outside of the submitted work. P.N.B. acknowledges consulting fees from Resolution Therapeutics and payment or honoraria for lectures from Takeda, outside of the submitted work. D.I.W., H.E.M., C.J.K. and N.C. declare no competing interests.

Rights and permissions

About this article

Cite this article

Lazarus, J.V., Ivancovsky Wajcman, D., Mark, H.E. et al. Opportunities and challenges following approval of resmetirom for MASH liver disease.Nat Med 30, 3402–3405 (2024). https://doi.org/10.1038/s41591-024-02958-z

Download citation